Skip to main content
SpringerLink
Log in

Interleukin-6 and Castleman’s Disease

  • Chapter
Book cover Cytokines in the Genesis and Treatment of Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 925 Accesses

Abstract

In 1956, Castleman et al. reported 13 patients who had localized mediastinal lymph node hyperplasia resembling thymoma (1). The characteristic features of the hyperplastic lymph nodes were follicular hyperplasia with a large germinal center penetrated by branching hyaline blood vessels and proliferation of hyaline capillaries with endothelial hyperplasia in the interfollicular areas. Thereafter, Flendrig et al. and Keller et al. independently reported another morphologic type of the benign giant lymph node characterized by hyperplastic germinal centers and intervening sheets of plasma cells (2,3). The former is referred to as the hyaline-vascular type (HV type) and the latter as the plasma cell type (PC type) of Castleman’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822-830.

    Google Scholar 

  2. Flendrig JA, Schillings PHM. Benign giant lymphoma: The clinical signs and symptoms. Folia Med Neerl 1969;12:119–120.

    Google Scholar 

  3. Keller AR, Hochholzer L, Castleman B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670–683.

    Article  CAS  PubMed  Google Scholar 

  4. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86–90.

    CAS  PubMed  Google Scholar 

  5. Bartoli E, Massarelli G, Soggia G, et al. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 1980;73:423–426.

    CAS  PubMed  Google Scholar 

  6. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases. Hum Pathol 1985;156:162–172.

    Article  Google Scholar 

  7. Diebold J, Tulliez M, Bernadou A, et al. Angiofollicular and plasmacytic polyadenopathy: A pseudotumourous syndrome with dysimmunity. J Clin Pathol 1980;33:1068–1070.

    Article  CAS  PubMed  Google Scholar 

  8. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78.

    Article  CAS  PubMed  Google Scholar 

  9. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989;74:1360–1367.

    CAS  PubMed  Google Scholar 

  10. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin-6 in Castleman’s disease. Hum Pathol 1993;24:833–839.

    Article  CAS  PubMed  Google Scholar 

  11. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602–605.

    Article  CAS  PubMed  Google Scholar 

  12. Frizzera G. Castleman’s disease: More questions than answers. Hum Pathol 1985; 16:202–205.

    Article  CAS  PubMed  Google Scholar 

  13. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202–1216.

    CAS  PubMed  Google Scholar 

  14. Kessier E: Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer 1985:56; 2446–2451.

    Article  Google Scholar 

  15. Johkoh T, Muller LN, Ichikado K, et al. Intrathoracic multicentric Castleman disease; CT findings in 12 patients. Radiology 1998; 209:477–481.

    CAS  PubMed  Google Scholar 

  16. Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: The POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980;59:311–322.

    Article  CAS  PubMed  Google Scholar 

  17. Hanson CA, Frizzera G, Patton DF et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman’s disease. Association with Epstein-Barr virus. Am J Pathol 1988;131:84–91.

    CAS  PubMed  Google Scholar 

  18. Nagai M, Irino S, Uda H, et al. Molecular genetic and immunohistochemical analyses of a case of multicentric Castleman disease. Jpn J Clin Oncol 1988;18:149–157.

    CAS  PubMed  Google Scholar 

  19. Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol 1993;20:636–647.

    CAS  PubMed  Google Scholar 

  20. Pavlidis NA, Skopouli FN, Bai MC, et al. A successfully treated case of multicentric angiofollicular hyperlasia with oral chemotherapy (Castleman’s desease). Med Pediatr Oncol 1990;18:333–335.

    Article  CAS  PubMed  Google Scholar 

  21. Feigert JM, Sweet DL, Coleman M, et al. Multicentric angiogollicular lymph node hyperplasia with peripheral neuropathy, pseudotumor ceebri, IgA dysproteinemia, and thrombocytosis in women. A distinct syndrome. Ann Intern Med 1990;l 13:362–367.

    Google Scholar 

  22. Muraguchi A, Kishimoto T, Miki T, et al. T cell-replacing factor (TRF)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 1981;127:412–416.

    CAS  PubMed  Google Scholar 

  23. Yoshizaki K, Nakagawa T, Kaieda T, et al. Induction of proliferation and Igs-production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol 1982;128:1296–1301.

    CAS  PubMed  Google Scholar 

  24. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin(BSF-2) that induces B cell lymphocytes to produce immunoglobulin. Nature 1986;324:73–76.

    Article  CAS  PubMed  Google Scholar 

  25. Zilberatein A, Ruggieri R, Korn JH, et al. Structure and expression of cDNA and genes for human interferon-β2, a distinct species inducible by growth-stimulatory cytokines. EMBO J1986;5:2529–2537.

    Google Scholar 

  26. Sehgal PB, Walther Z, and Tamm I. Rapid enhancement of β2-interferon/ B-cell differntiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and calcium ionophore A23187. Proc Natl Acad Sci USA 1987;84:3633–3667.

    Article  Google Scholar 

  27. Haegeman G, Content J, Volckaert G, et al. Structural analysis of the sequence encoding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem 1986;159:625–632.

    Article  CAS  PubMed  Google Scholar 

  28. Van Damme J, Opdenakker G, Simpson RJ, et al. Identification of the human 26-kDa protein, interferon β2 (IFNβ2), as a B cell hybridoma/ plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 1987;165:914–919.

    Article  PubMed  Google Scholar 

  29. Nordan RP, Pumphrey JG, Rudikoff S. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol 1987;139:813–817.

    CAS  PubMed  Google Scholar 

  30. Andus T, Geiger T, Hirano T, et al. Recombinant human B cell stimulatory factor 2 (BSF-2/IFNβ2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett 1987;221:18–22.

    Article  CAS  PubMed  Google Scholar 

  31. Gauldie J, Richards C, Harnish D, et al. Interferon-β2/ B cell-stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251–7255.

    Article  CAS  PubMed  Google Scholar 

  32. Castell JV, Gomez-Lechon MJ, David M, et al. Recombinant human interleukin-6 (IL-6/ BSF-2/ HSF) regurates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347–350.

    Article  CAS  PubMed  Google Scholar 

  33. Noma T, Mizuta T, Rosen A, et al. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 1987;15:249–253.

    Article  CAS  PubMed  Google Scholar 

  34. Miyaura C, Onozaki K, Akiyama Y, et al. Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (Ml). FEBS Lett 1988;234:17–21.

    Article  CAS  PubMed  Google Scholar 

  35. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989;74:1241–1244.

    CAS  PubMed  Google Scholar 

  36. Ikebuchi K, Wong GG, Clark SC, et al. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987;84:9035–9039.

    Article  CAS  PubMed  Google Scholar 

  37. Koike K, Nakahata T, Takagi M, et al. Synergism of BSF2/ interleukin-6 and interleukin-3 on development of multipotential hemopoietic progenitors in serum free culture. J Exp Med 1988; 168:879–890.

    Article  CAS  PubMed  Google Scholar 

  38. Ulich TR, del Castillo J, Guo KZ. In vivo hematologie effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 1989;73:108–110.

    CAS  PubMed  Google Scholar 

  39. Horii Y, Muraguchi A, Iwano M, et al. Involvement of interleukin-6 in mesangial proliferative of glomerulonephritis. J Immunol 1989;143:3949–3955.

    CAS  PubMed  Google Scholar 

  40. Yee C, Biondi A, Wang XH, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989;74:798–804.

    CAS  PubMed  Google Scholar 

  41. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83–85.

    Article  CAS  PubMed  Google Scholar 

  42. Miles SA, Rezai AR, Salazar-Gonzales JF, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87:4068–4072.

    Article  CAS  PubMed  Google Scholar 

  43. Suematsu S, Matsuda T, Aozasa K, et al. IgGl plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 1989;86:7547–7551.

    Article  CAS  PubMed  Google Scholar 

  44. Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 1992;89: 232–235.

    Article  CAS  PubMed  Google Scholar 

  45. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304–311.

    Article  CAS  PubMed  Google Scholar 

  46. Akira S, Isshiki H, Sugita T, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990;9:1897–1906.

    CAS  PubMed  Google Scholar 

  47. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995;14:1932–1941.

    CAS  PubMed  Google Scholar 

  48. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865–1869.

    Article  CAS  PubMed  Google Scholar 

  49. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276–1280.

    CAS  PubMed  Google Scholar 

  50. Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman’s disease. N Engl J Med 1995;333:798–799.

    CAS  PubMed  Google Scholar 

  51. Gessain A, Sudaka A, Briere J, et al. Kaposi’s sarcoma-associated herpesvirus-like Virus (Human Herpesvirus Type 8) DNA sequences in multicentric Castleman’s disease: Is there any relevant association in nonhuman immunodeficiency virus-infected patients? Blood 1996;87:414–416.

    CAS  PubMed  Google Scholar 

  52. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93:14862–14867.

    Article  CAS  PubMed  Google Scholar 

  53. Moor P S, Boshoff C, Weiss RA, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739–1744.

    Article  Google Scholar 

  54. Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi’s sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nature Med 1997;3:287–292.

    Article  CAS  PubMed  Google Scholar 

  55. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997;71:839–842.

    CAS  PubMed  Google Scholar 

  56. Chen KT. Multicentric Castleman’s disease and Kaposi’s sarcoma. Am J Surg Pathol 1984; 8:287–293.

    Article  CAS  PubMed  Google Scholar 

  57. Dickson D, Ben-Ezra JM, Reed J, et al. Multicentric giant lymph node hyperplasia, Kaposi’s sarcoma, and lymphoma. Arch Pathol Lab Med 1985;109:1013–1018.

    CAS  PubMed  Google Scholar 

  58. De Rosa G, Barra E, Guarino M, et al. Multicentric Castleman’s disease in association with Kaposi’s sarcoma. Appl Pathol 1989;7:105–110.

    PubMed  Google Scholar 

  59. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcomaassociated herpesvirus-encoded interleukin-6. Blood 1999;93:4034–4043.

    CAS  PubMed  Google Scholar 

  60. Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 1999;94:4247–4254.

    CAS  PubMed  Google Scholar 

  61. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol 1997;151:1517–1522.

    CAS  PubMed  Google Scholar 

  62. Mori Y, Nishimoto N, Ohno M, et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol 2000;61:332–335.

    Article  CAS  PubMed  Google Scholar 

  63. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/INF b2) receptor. Science 1988;241:825–828.

    Article  CAS  PubMed  Google Scholar 

  64. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gpl30. Cell 1989;58:573–581.

    Article  CAS  PubMed  Google Scholar 

  65. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gpl30. Cell 1990;63:1149–1157.

    Article  CAS  PubMed  Google Scholar 

  66. Heinrich PC, Graeve L, Rose-John S, et al. Membrane-bound and soluble interleukin-6 receptor: studies on structure, regulation of expression, and signal transduction. Ann N Y Acad Sci 1995;762: 222–366.

    Article  CAS  PubMed  Google Scholar 

  67. Ogata A, Nishimoto N, Shima Y, et al. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040–3046.

    CAS  PubMed  Google Scholar 

  68. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53:851–856.

    CAS  PubMed  Google Scholar 

  69. Nishimoto N, Ogata A, Shima Y, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994; 179:1343–1347.

    Article  CAS  PubMed  Google Scholar 

  70. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-IL-6 receptor antibody therapy. Blood 2000;95:56–61.

    CAS  PubMed  Google Scholar 

  71. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30:1426–1435.

    CAS  PubMed  Google Scholar 

  72. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interteukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627–2632.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan

    Norihiro Nishimoto MD, PHD (Professor)

Authors
  1. Norihiro Nishimoto MD, PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University Comprehensive Cancer Center, Columbus, OH

    Michael A. Caligiuri MD

  2. University of Pittsburgh Cancer Center, Pittsburgh, PA

    Michael T. Lotze MD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Nishimoto, N. (2007). Interleukin-6 and Castleman’s Disease. In: Caligiuri, M.A., Lotze, M.T. (eds) Cytokines in the Genesis and Treatment of Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-455-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-455-1_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-820-2

  • Online ISBN: 978-1-59745-455-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation